FREE Account Opening + No Clearing Fees

Kids Medical BSE SME IPO review (Avoid)

Review By Dilip Davda on December 7, 2017

Kids Medical Systems Ltd. (KMS) is engaged in providing solution in healthcare sector as pediatric clinic chain provider. It offers exclusive services which can benefit the child for their healthcare needs. it partner with doctors at a clinic /premise level. KMS offers services which can assist and help doctors to manage, educate and develop their clinic, its infrastructure, its people and most importantly also provide guidance in services to parents of the child. The company also assists in all services like timely reminders on vaccinations and other services are offered to parents proactively as it understand a proper communication, and better service standards offered at the time of distress where immediate child healthcare services are required. KMS provides the service Management/Light Asset Model which includes the clinic Management Software, clinic reports, Training, recruitment of staff, Online and Offline engagement with customers. In addition it also provide Glow sign Boards, Paraphernalia, Standees and also arrange for co-branding marketing efforts, as and when required in Pre-School, Schools, mailers, SMS, whatsApp or other electronic or through other devices or modes. KMS started with 1(one) clinic in Dombivali (Thane District- Maharastra) and reached to 15 (Fifteen) Hospitals/Doctors with whom it entered into Management Partnership/ Franchisee agreements/Revenue sharing arrangement till date.

To part finance setting up of clinics and purchase of its interiors with allied infrastructure, working capital and general corpus fund needs, KMS is coming out with a maiden IPO of 2000000 equity shares of Rs. 10 each at a fixed price of Rs. 30 per share to mobilize Rs. 6.00 crore. Issue opens for subscription on 11.12.17 and will close on 14.12.17. Minimum application is to be made for 4000 shares and in multiples thereon, thereafter. Post allotment shares will be listed on BSE SME. Issue is solely lead managed by Gretex Corporate Services Pvt Ltd and Purva Sharegistry (India) Pvt. Ltd. is the registrar to the issue. Issue constitutes 28.20% of the post issue paid up capital of the company. The average cost of acquisition of shares by the promoters is ranging from Rs. 1.86 to Rs. 9.77 per share. Having issued equity at par on MoA, it raised further equity in the price range of Rs.330 to Rs. 12500 per share between November 2015 and August 2017, and has also issued bonus shares in the ratio of 30 for 1 in September 2017. Post issue, its current paid up equity capital of Rs. 5.09 crore will stand enhanced to Rs. 7.09 crore.

On performance front, KMS has posted turnover/net profits of Rs. 0.24 cr. / Rs. – (0.41) cr. (FY14), Rs. 0.59 cr. / Rs. – (0.79) cr. (FY15), Rs. 0.96 cr./ Rs. – (1.11) cr. (FY16) and Rs. 2.26 cr. / Rs. 0.14 cr. (FY17). Thus FY 17 witnessed surprising results. For the period ended on 05.09.17 of the current fiscal, it has earned net profit of Rs. 0.03 cr. on a turnover of Rs.0.32 cr. Issue is priced at a P/BV of 2.81 and 1.86 on the basis of its NAV as on 05.09.17 as well as post issue. For last three fiscals it has posted an average EPS of Rs. - (0.87) and average RoNW of – (0.84) %. If we annualize latest earnings and attribute on fully diluted equity post issue, then asking price is at a P/E of 31 plus, thus issue is aggressively priced. It has not listed peers to compare with.

On merchant banker's front, this is the 10th mandate from its stable in past three years. Out of last 8 listings 3 opened at discount, 4 at par and 1 with just 0.40% premium to offer price on the day of listings. Thus it has poor track record.

Conclusion: There is no harm in giving this highly priced issue a miss. (Avoid).

Conclusion / Investment Strategy

There is no harm in giving this highly priced issue a miss. (Avoid). The asking price is at a P/E of 31 plus, thus issue is aggressively priced.

Reviewer recommends Avoid to the issue.

Review By Dilip Davda on December 7, 2017

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: ).

Kids Medical Systems IPO FAQs

  1. 1. Why Kids Medical Systems IPO?

    The initial public offer (IPO) of Kids Medical Systems Limited offers an early investment opportunity in Kids Medical Systems Limited. A stock market investor can buy Kids Medical Systems IPO shares by applying in IPO before Kids Medical Systems Limited shares get listed at the stock exchanges. An investor could invest in Kids Medical Systems IPO for short term listing gain or a long term.

  2. 2. How is Kids Medical Systems IPO?

    Read the Kids Medical Systems IPO recommendations by the leading analyst and leading stock brokers.

  3. 3. Kids Medical Systems IPO what should investors do?

    Kids Medical Systems IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Kids Medical Systems IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  4. 4. Is Kids Medical Systems IPO good?

    Our recommendation for Kids Medical Systems IPO is to avoid.

  5. 5. Is Kids Medical Systems IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to avoid the Kids Medical Systems IPO.

  6. 6. When will Kids Medical Systems IPO allotment status?

    The Kids Medical Systems IPO allotment status will be available on or around [.]. The allotted shares will be credited in demat account by [.]. Visit Kids Medical Systems IPO allotment status to check.

  7. 7. When will Kids Medical Systems IPO list?

    The Kids Medical Systems IPO will list on Friday, December 22, 2017, at BSE SME.